WO2013044736A1 - Traditional chinese medicine composition for external use in treating xerophthalmia and the preparation method thereof - Google Patents

Traditional chinese medicine composition for external use in treating xerophthalmia and the preparation method thereof Download PDF

Info

Publication number
WO2013044736A1
WO2013044736A1 PCT/CN2012/081389 CN2012081389W WO2013044736A1 WO 2013044736 A1 WO2013044736 A1 WO 2013044736A1 CN 2012081389 W CN2012081389 W CN 2012081389W WO 2013044736 A1 WO2013044736 A1 WO 2013044736A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
chinese medicine
traditional chinese
medicine composition
Prior art date
Application number
PCT/CN2012/081389
Other languages
French (fr)
Chinese (zh)
Inventor
金明
Original Assignee
Jin Ming
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jin Ming filed Critical Jin Ming
Publication of WO2013044736A1 publication Critical patent/WO2013044736A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287Chrysanthemum, e.g. daisy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • A61K36/428Trichosanthes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969Polygonatum (Solomon's seal)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to a pharmaceutical composition and a preparation method thereof, in particular to a traditional Chinese medicine composition for external treatment of dry eye and a preparation method thereof.
  • the tear film can no longer afford its barrier, immune regulation and mechanical removal of debris and antimicrobial effects, the sensory nerve-rich cornea is directly exposed to the outside world, plus viscous debris deposited in the conjunctival ridge and the filamentous cornea Exfoliation of the epithelium leads to a series of clinical symptoms. The most common symptoms are eye fatigue, foreign body sensation, dryness, burning sensation, long-sightedness, eyesight, photophobia, and redness.
  • the measures for prevention and treatment of dry eye are relatively limited.
  • the artificial tears are relieved for a long time, but the preservative has a detrimental effect on the tear film; the moderate person can wear a silicone eye mask, a wet room mirror, a goggle, and therapeutic.
  • Contact lens or implanted small puncture embolus to maintain the retention of tears in the eye; severe cases of eyelid suture to prevent the occurrence of complication such as corneal degeneration.
  • the efficacy is not certain, and the problem of the patient's own tear quality and quantity cannot be fundamentally improved.
  • Another object of the present invention is to disclose a method for preparing a traditional Chinese medicine composition for external use for treating dry eye.
  • composition of the drug substance of the pharmaceutical composition of the present invention is:
  • the drug substance composition of the pharmaceutical composition of the present invention is preferably:
  • the drug substance composition of the pharmaceutical composition of the present invention is preferably:
  • the drug substance composition of the pharmaceutical composition of the present invention is preferably:
  • the preparation method of the above pharmaceutical composition of the present invention is as follows: taking astragalus, mint, trichosanthin, huangjing, chrysanthemum, adding 2-8 times (weight times) water for 1 to 4 times, each time for 30 to 150 minutes, combining the extracts, After filtration, the filtrate is concentrated to a clear paste having a relative density of 1.05 to 1.35, and the borneol and the clear paste are mixed, and a conventional excipient is added to prepare a clinically accepted dosage form.
  • the above dosage forms may be in the form of tablets, pills, granules, effervescent agents and the like.
  • composition preparation of the present invention is preferably administered by atomization by an ultrasonic atomizing device in clinical use.
  • the medicine is dissolved in hot water of 80-100 degrees Celsius, Dissolve the vapors that are emitted to fumigate the eye.
  • the preparation of the composition of the invention can be atomized and administered by connecting an ultrasonic atomizing device, and the preparation of the composition of the invention is placed in a container of the ultrasonic atomizer, and the medicine is atomized by the action of ultrasonic waves to form atomized molecules. Introduced into the ocular surface via a soft rubber tube.
  • the invention also provides a wet compress comprising the above composition
  • the preparation method of the wet compress is as follows: taking astragalus, mint, trichosanthin, huangjing, chrysanthemum, adding 2-8 times (weight times) water to extract 1 ⁇ 4 times Each time 30 ⁇ 150 minutes, the extracts were combined, filtered, and the filtrate was concentrated to a clear density of 1.05 ⁇ 1.35.
  • the borneol and the clear paste were mixed, mixed thoroughly, and then added with 40%-80% ethanol for 24 hours to precipitate. The ethanol is then recovered to an alcohol-free taste, and after refrigerated, it is placed in a non-woven carrier.
  • the traditional Chinese medicine composition has significant improvement effects in prolonging tear film breakage time, increasing tear flow, improving corneal staining, and improving conjunctival hyperemia.
  • Treatment of dry eye syndrome The statistical cure rate is 8.33%, the effective rate is 50.69%, the effective rate is 38.89%, the inefficiency is 2.09%, and the total effective rate is 97.91%.
  • the traditional Chinese medicine composition has good effect for treating dry eye syndrome. effect.
  • Tear secretion test Measure the amount of tear base production. In the absence of surface anesthesia, place the Schirmer test paper (), one end folded in the middle and outer 1/3 of the lower jaw, drooping along the rim, and remove the filter paper after 5 minutes to measure the length of the tear soaked test paper. For example, ⁇ 5mm/5min is strongly positive ( ++ ), ⁇ 10mm/5min is positive ( + ).
  • asymptomatic score is 0, symptomatic frequency is ⁇ 3 times/week, and after relaxation, it can be relieved to 1 point, between 1 and 5 points.
  • symptomatic frequency is ⁇ 3 times/week, and after relaxation, it can be relieved to 1 point, between 1 and 5 points.
  • symptoms often appear, affecting quality of life and work, medication can be relieved to 5 points, symptoms appear between 5 ⁇ 9 points for 6 ⁇ 8 points, continue to appear, seriously affecting quality of life, medication can not alleviate It is 9 points.
  • efficacy index ( ⁇ ) [ ' total score before treatment - total score after treatment) ⁇ total score before treatment] X 100%. ⁇ >70% is markedly effective; 70%> ⁇ >30% is effective; ⁇ 30% is invalid; ⁇ 0 is force weight.
  • Burning sensation 8 ( 22.9% ) 4 ( 50.0% ) 3 ( 37.5% ) 1 ( 12.5% ) 0
  • the traditional Chinese medicine composition has significant improvement effects in prolonging tear film breakage time, increasing tear flow, improving corneal staining, and improving conjunctival hyperemia.
  • Treatment of dry eye syndrome The statistical cure rate is 8.33%, the effective rate is 50.69%, the effective rate is 38.89%, the inefficiency is 2.09%, and the total effective rate is 97.91%; indicating that the traditional Chinese medicine composition has good treatment for dry eye syndrome. The role.
  • Astragalus 40g 10g of mint, 10g of trichosanthin, 30g of Polygonatum, 20g of chrysanthemum, respectively, remove, wash, dry, add 6 times (weight) water extraction 3 times, each time 120 minutes, combine the extract, filter, take The filtrate was concentrated to a clear density of 1.15.
  • the borneol 3g and the clearing paste were mixed, and the tablet was added to a conventional excipient to prepare a tablet. When used, the tablet was fumigated with hot water to dissolve the steam.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Traditional Chinese medicine composition for external use in treating xerophthalmia and preparation method thereof, wherein the raw material of the traditional Chinese medicine composition consists of Radix Scutellariae, Herba Menthae, Radix Trichosanthis, Flos Chrysanthemi, Rhizoma Polygonati and Broneolum Syntheticum.

Description

一种外用治疗干眼症的中药组合物及其制备方法  Traditional Chinese medicine composition for external treatment of dry eye syndrome and preparation method thereof
技术领域 Technical field
本发明涉及一种药物组合物及其制备方法, 特别涉及外用治疗干眼症的 中药组合物及其制备方法。  The invention relates to a pharmaceutical composition and a preparation method thereof, in particular to a traditional Chinese medicine composition for external treatment of dry eye and a preparation method thereof.
背景技术 Background technique
随着社会发展和生活节奏的加快, 以干眼症为代表的职业病已变成了眼 科常见病、 多发病、 难治病。 调查显示: 美国 43〜84岁间占 13. 3%, 日本为 17.0%, 加拿大为 28.7%, 澳大利亚为 10. 3%。 干眼症病因繁多, 病理过程复 杂, 是眼科临床常见的目艮表疾病, 患者泪液分泌明显减少或泪液成分异常, 泪膜破裂时间缩短, 角膜上皮点状脱落, 荧光素染色呈阳性。 由于泪膜不再 能承担其屏障、 免疫调节和机械性清除碎屑及抗微生物作用, 感觉神经丰富 的角膜直接暴露于外界, 加上沉积在结膜嚢的粘性碎屑和卷成丝状的角膜剥 脱上皮的刺激, 导致患者出现一系列临床症状, 最常见的症状是眼疲劳、 异 物感、 干涩感, 或烧灼感、 目艮长感、 目艮痛、 畏光、 眼红等。  With the acceleration of social development and the pace of life, occupational diseases represented by dry eye have become common diseases, frequently-occurring diseases, and refractory diseases in ophthalmology. The survey shows that the United States accounted for 13.3% between 43 and 84 years old, 17.0% in Japan, 28.7% in Canada and 10.3% in Australia. The causes of dry eye syndrome are numerous and the pathological process is complicated. It is a common eye disease in ophthalmology. The tear secretion is obviously reduced or the tear component is abnormal. The tear film rupture time is shortened, the corneal epithelium is detached, and fluorescein staining is positive. Since the tear film can no longer afford its barrier, immune regulation and mechanical removal of debris and antimicrobial effects, the sensory nerve-rich cornea is directly exposed to the outside world, plus viscous debris deposited in the conjunctival ridge and the filamentous cornea Exfoliation of the epithelium leads to a series of clinical symptoms. The most common symptoms are eye fatigue, foreign body sensation, dryness, burning sensation, long-sightedness, eyesight, photophobia, and redness.
干眼症的病因极其复杂, 人们生活、 工作环境的改善, 空调、 电脑等的 普及, 干眼症的发病率较以前明显增加。 有资料认为干眼症的发病率因电脑 的出现每年增加 10%。 现临床上由于 "眼不适", 而就诊的患者越来越多, 其 中很大一部分可能是干眼症。 但治疗时作为一般炎症处理, 患者症状始终未 能完全消失或改善, 甚至加重, 这将导致严重的眼表疾病, 包括角膜表面磨 损丝状角膜炎和角膜溃疡等并发症并最终导致角膜混浊和视力丧失的严重后 果。  The causes of dry eye syndrome are extremely complicated, people's living and working environment are improved, and the popularity of air conditioners and computers is increasing. The incidence of dry eye syndrome is significantly higher than before. There is information that the incidence of dry eye is increased by 10% per year due to the emergence of computers. There are more and more patients in the clinic due to "eye discomfort", and a large part of them may be dry eye syndrome. However, as a general inflammatory treatment during treatment, the patient's symptoms have not completely disappeared or improved, and even worsened, which will lead to serious ocular surface diseases, including complications such as corneal surface abrasion stellate keratitis and corneal ulcer, and eventually lead to corneal opacity and The serious consequences of vision loss.
目前防治干眼症措施比较局限,轻者以长期滴 "人工泪液,,緩解症状,但防 腐剂对泪膜有损害作用; 中度者可配戴硅胶眼罩、 湿房镜、 潜水镜、 治疗性 角膜接触镜或植入泪小点栓子以维持泪液在眼内的存留; 重者进行眼睑缝合 术, 以防止角膜变性等合并症的发生。 总之, 治疗方法虽多, 但其弊端也多, 疗效尚不肯定, 不能从根本上改善患者自身泪液质和量的问题。 At present, the measures for prevention and treatment of dry eye are relatively limited. In the light, the artificial tears are relieved for a long time, but the preservative has a detrimental effect on the tear film; the moderate person can wear a silicone eye mask, a wet room mirror, a goggle, and therapeutic. Contact lens or implanted small puncture embolus to maintain the retention of tears in the eye; severe cases of eyelid suture to prevent the occurrence of complication such as corneal degeneration. In short, although there are many treatment methods, but there are many drawbacks. The efficacy is not certain, and the problem of the patient's own tear quality and quantity cannot be fundamentally improved.
发明内容 Summary of the invention
本发明的目的是公开一种外用治疗干眼症的中药组合物。  It is an object of the present invention to disclose a traditional Chinese medicine composition for external use for treating dry eye.
本发明的另一个目的是公开一种外用治疗干眼症的中药组合物的制备方 法。  Another object of the present invention is to disclose a method for preparing a traditional Chinese medicine composition for external use for treating dry eye.
本发明的目的是由如下技术方案实现的:  The object of the present invention is achieved by the following technical solutions:
本发明药物组合物的原料药组成为:  The composition of the drug substance of the pharmaceutical composition of the present invention is:
黄芩 5-50重量份 薄荷 3-45重量份 天花粉 5-50重量份 菊花 1-40重量份 黄精 3-45重量份 冰片 0.1-5重量份。 本发明药物组合物的原料药组成优选为:  Astragalus 5-50 parts by weight Mint 3-45 parts by weight Trichosanthin 5-50 parts by weight Chrysanthemum 1-40 parts by weight Yellow essence 3-45 parts by weight Boring piece 0.1-5 parts by weight. The drug substance composition of the pharmaceutical composition of the present invention is preferably:
黄芩 10-40重量份 薄荷 5-35重量份 天花粉 10-40重量份 菊花 5-30重量份 黄精 5-35重量份 冰片 0.5-3重量份。 本发明药物组合物的原料药组成优选为:  Astragalus 10-40 parts by weight Mint 5-35 parts by weight Trichosanthin 10-40 parts by weight Chrysanthemum 5-30 parts by weight Yellow essence 5-35 parts by weight Boring piece 0.5-3 parts by weight. The drug substance composition of the pharmaceutical composition of the present invention is preferably:
黄芩 15-30重量份 薄荷 10-25重量份 天花粉 15-30重量份 菊花 7-20重量份 黄精 10-25重量份 冰片 0.7-1.5重量份 本发明药物组合物的原料药组成优选为:  Astragalus 15-30 parts by weight Mint 10-25 parts by weight Trichosanthin 15-30 parts by weight Chrysanthemum 7-20 parts by weight Yellow essence 10-25 parts by weight Boring piece 0.7-1.5 parts by weight The drug substance composition of the pharmaceutical composition of the present invention is preferably:
黄芩 20重量份 薄荷 15重量份 天花粉 20重量份  Astragalus 20 parts by weight Mint 15 parts by weight Trichosanthin 20 parts by weight
菊花 10重量份 黄精 15重量份 冰片 1重量份  Chrysanthemum 10 parts by weight Huang Jing 15 parts by weight Boron 1 part by weight
上述本发明药物组合物的制备方法为: 取黄芩、 薄荷、 天花粉、 黄精、 菊花, 加 2 ~ 8倍量 (重量倍 )水提取 1 ~ 4次, 每次 30 ~ 150分钟, 合并提 取液, 过滤, 取滤液浓缩成相对密度为 1.05 ~ 1.35 的清膏, 将冰片和清膏混 合, 加入常规辅料制成临床接受的剂型。  The preparation method of the above pharmaceutical composition of the present invention is as follows: taking astragalus, mint, trichosanthin, huangjing, chrysanthemum, adding 2-8 times (weight times) water for 1 to 4 times, each time for 30 to 150 minutes, combining the extracts, After filtration, the filtrate is concentrated to a clear paste having a relative density of 1.05 to 1.35, and the borneol and the clear paste are mixed, and a conventional excipient is added to prepare a clinically accepted dosage form.
上述剂型可以是片剂、 丸剂、 颗粒剂、 泡腾剂等形式。  The above dosage forms may be in the form of tablets, pills, granules, effervescent agents and the like.
本发明组合物制剂临床使用时优选通过超声雾化装置雾化给药。  The composition preparation of the present invention is preferably administered by atomization by an ultrasonic atomizing device in clinical use.
本发明组合物制剂临床使用时, 将药物用 80-100摄氏度的热水溶解, 用 溶解散发出的蒸汽对眼部进行熏蒸, When the preparation of the composition of the invention is used clinically, the medicine is dissolved in hot water of 80-100 degrees Celsius, Dissolve the vapors that are emitted to fumigate the eye.
本发明组合物制剂在临床上可通过连接超声雾化装置进行雾化给药, 即 将本发明组合物制剂置入超声波雾化仪的容器, 通过超声波的作用使药物雾 化, 形成雾化分子, 经软橡胶管导入眼表。  The preparation of the composition of the invention can be atomized and administered by connecting an ultrasonic atomizing device, and the preparation of the composition of the invention is placed in a container of the ultrasonic atomizer, and the medicine is atomized by the action of ultrasonic waves to form atomized molecules. Introduced into the ocular surface via a soft rubber tube.
本发明还提供一种包含上述组合物的湿敷剂, 湿敷剂的制备方法为: 取黄芩、 薄荷、 天花粉、 黄精、 菊花, 加 2 ~ 8倍量 (重量倍 )水提取 1 ~ 4次,每次 30 ~ 150分钟,合并提取液,过滤,取滤液浓缩成相对密度为 1.05 ~ 1.35的清膏,将冰片和清膏混合,充分混合后加入 40%-80%乙醇沉淀 24小时, 沉淀后回收乙醇至无醇味, 冷藏后装于无纺布载体中。  The invention also provides a wet compress comprising the above composition, the preparation method of the wet compress is as follows: taking astragalus, mint, trichosanthin, huangjing, chrysanthemum, adding 2-8 times (weight times) water to extract 1 ~ 4 times Each time 30 ~ 150 minutes, the extracts were combined, filtered, and the filtrate was concentrated to a clear density of 1.05 ~ 1.35. The borneol and the clear paste were mixed, mixed thoroughly, and then added with 40%-80% ethanol for 24 hours to precipitate. The ethanol is then recovered to an alcohol-free taste, and after refrigerated, it is placed in a non-woven carrier.
本中药组合物在延长泪膜破碎时间, 增加泪液流量、 改善角膜染色、 改善 结膜充血症状等方面, 都有显著改善效果。 对干眼症的治疗: 经统计痊愈率 8.33%, 显效率为 50.69%, 有效率为 38.89%, 无效率 2.09%, 总有效率为 97.91%; 本中药组合物对于治疗干眼症具有良好的作用。  The traditional Chinese medicine composition has significant improvement effects in prolonging tear film breakage time, increasing tear flow, improving corneal staining, and improving conjunctival hyperemia. Treatment of dry eye syndrome: The statistical cure rate is 8.33%, the effective rate is 50.69%, the effective rate is 38.89%, the inefficiency is 2.09%, and the total effective rate is 97.91%. The traditional Chinese medicine composition has good effect for treating dry eye syndrome. effect.
实验例 1临床实验资料 Experimental example 1 clinical experimental data
1、 资料与方法  1, data and methods
1.1一般资料 144例均为门诊病人,男 70例,女 84例;年龄 23 ~ 81岁, 平均年龄(45.6±8.2 ) 岁。  1.1 General Information 144 cases were outpatients, 70 males and 84 females; aged 23-81 years, mean age (45.6 ± 8.2) years.
1.2诊断标准 本次釆用我国张汗承教授 1987年制定的标准 [2] , 传统三 项检查法包括 Schirmer I试验、 BUT测定及角膜荧光染色。  1.2 Diagnostic criteria This time, the standard developed by Professor Zhang Hancheng of China in 1987 [2], the traditional three examination methods include Schirmer I test, BUT measurement and corneal fluorescence staining.
1.3诊断方法 :  1.3 diagnosis method:
1. 3. 1 泪液分泌试验( Schirmer ): 测量泪液基础生成量。 在无表面麻 醉情况下, 将 Schirmer试纸(), 一端折放于下睑中外 1/3穹窿部, 沿睑缘下 垂, 5分钟后取下滤纸, 测量泪液浸湿试纸的长度。 如 < 5mm/5min为强阳性 ( ++ ), < 10mm/5min为阳性( + )。  1. 3. 1 Tear secretion test (Schirmer): Measure the amount of tear base production. In the absence of surface anesthesia, place the Schirmer test paper (), one end folded in the middle and outer 1/3 of the lower jaw, drooping along the rim, and remove the filter paper after 5 minutes to measure the length of the tear soaked test paper. For example, < 5mm/5min is strongly positive ( ++ ), < 10mm/5min is positive ( + ).
1. 3. 2 泪膜破碎时间 (BUT ): 反应泪膜的稳定性。 用玻璃棒蘸荧光素 钠点于患者下眼睑, 嘱患者闭眼, 在裂隙灯下观察患者从睁开眼到角膜表面 出现第一个黑斑之间的时间, 此间隔即 BUT。 < 10s为阳性( + )。 1. 3. 3角膜荧光素染色: 反应角膜上皮缺损情况。 无染色为 0分, 每个 象限分轻、 中、 重 3级, 因此共 0 ~ 12分, 一般认为<1分为正常。 1. 3. 2 tear film break time (BUT): Respond to the stability of the tear film. Using a glass rod, fluorescein sodium was applied to the lower eyelid of the patient, and the patient was closed. The time between the opening of the eye and the appearance of the first dark spot on the surface of the cornea was observed under a slit lamp, which is the BUT. < 10s is positive ( + ). 1. 3. 3 corneal fluorescein staining: reaction corneal epithelial defect. No staining is 0 points, each quadrant is divided into light, medium and heavy grades, so a total of 0 ~ 12 points, it is generally considered that <1 is normal.
1.4症状评分: 干眼的诊断依据在没有体征时取决于主观症状:  1.4 Symptom score: The diagnosis of dry eye depends on subjective symptoms in the absence of signs:
根据 2004年《全国干眼的诊断与治疗进展研讨会》标准规定: 无症状为 0分、有症状出现频率<3次 /周,休息后能緩解为 1分、介于 1 ~ 5分之间为 2 ~ 4分、 症状经常出现, 影响生活质量及工作, 用药才能緩解为 5分、 症状出现 介于 5 ~ 9分之间为 6 ~ 8分、 持续出现, 严重影响生活质量, 用药不能緩解 为 9分。  According to the 2004 National Symposium on Diagnosis and Treatment of Dry Eyes, the criteria are as follows: asymptomatic score is 0, symptomatic frequency is <3 times/week, and after relaxation, it can be relieved to 1 point, between 1 and 5 points. For 2 ~ 4 points, symptoms often appear, affecting quality of life and work, medication can be relieved to 5 points, symptoms appear between 5 ~ 9 points for 6 ~ 8 points, continue to appear, seriously affecting quality of life, medication can not alleviate It is 9 points.
根据记分法判定疗效:疗效指数 (η)=[ '台疗前总记分-治疗后总记分) ÷治疗 前总记分] X 100%。 η>70%为显效; 70%>η>30%为有效; η<30%为无效; η<0 为力口重。  Efficacy was determined according to the scoring method: efficacy index (η) = [ ' total score before treatment - total score after treatment) 总 total score before treatment] X 100%. η>70% is markedly effective; 70%>η>30% is effective; η<30% is invalid; η<0 is force weight.
1.5治疗方法  1.5 treatment methods
1.5.1中药制剂  1.5.1 Chinese medicine preparation
组方: 黄芩 20g、 薄荷 15g、 天花粉 20g、 菊花 10g、 黄精 15g、 冰片 lg; 上述组方加水 (常规水量)煎煮 2次,合并煎液,加入冰片, 得药浓煎 100毫 升。  Recipe: Astragalus 20g, Mint 15g, Trichosanthin 20g, Chrysanthemum 10g, Polygonatum 15g, Borneol lg; The above formula is added with water (conventional water) for 2 times, combined with decoction, added with borneol, and the drug is concentrated to 100 ml.
1.5.2使用方法  1.5.2 How to use
每次将 1.5.1 中药煎剂 20ml放入超声波低温雾化器容器中, 用雾化管接 通, 通过超声振动使药液形成雾化分子直接作用于眼部, 低温凉雾冷熏温度 低于眼睑周围空气温度约 3°C ~ 5°C , 控制在 8°C ~ 17°C。 此控制范围与幅度 均以温度计测试观察统计。 患者张开眼险接受治疗, 喷雾口离眼睛约 2 ~ 3cm, 雾化量维持在 2ml/min以上, 每次 20min, 每日 1次, 7次为 1个疗程, 一个 疗程后统计疗效。  Each time, 1.15 Chinese herbal decoction 20ml is placed in the ultrasonic low-temperature atomizer container, and connected with an atomizing tube. The ultrasonic wave is used to form the atomized molecules directly to the eye, and the low-temperature cold fog cold smoke temperature is low. The air temperature around the eyelid is about 3 ° C ~ 5 ° C, controlled at 8 ° C ~ 17 ° C. The range and magnitude of this control are measured by thermometer test observations. The patient opened the eye for treatment, the spray mouth was about 2 ~ 3cm away from the eyes, and the atomization amount was maintained at 2ml/min or more, 20min each time, once a day, 7 times for one course of treatment, and the therapeutic effect was measured after one course of treatment.
1.6统计方法  1.6 statistical methods
应用 SPSS17.0统计软件完成统计分析。 以 P < 0.05作为差异有显著性。 Statistical analysis was performed using SPSS 17.0 statistical software. The difference was significant at P < 0.05.
2.结果 2. Results
2.1总体疗效结果 由表 1 可以看出: 经过治疗的干眼症患者, 痊愈率 8.33%, 显效率为 50.69%, 有效率为 38.89%, 无效率 2.09%, 总有效率为 97.91%。 2.1 overall efficacy results It can be seen from Table 1 that the cure rate of dry eye patients is 8.33%, the effective rate is 50.69%, the effective rate is 38.89%, the inefficiency is 2.09%, and the total effective rate is 97.91%.
表 1 治疗前后症状体征疗效结果  Table 1 Results of symptoms and signs before and after treatment
例数 痊愈 ( % ) 显效(% ) 有效(% ) 无效(% ) 总有效率( % ) Case number Recovery (%) Effective (%) Effective (%) Invalid (%) Total efficiency (%)
144 12 (8.33) 73 ( 50.69 ) 56(38.89) 3 (2.09) 97.91% 144 12 (8.33) 73 ( 50.69 ) 56 (38.89) 3 (2.09) 97.91%
2.2 治疗前后症状体征积分比较结果 2.2 Comparison of symptoms and signs before and after treatment
由表 2可以看出, 患者主观症状及体征记分在治疗前后有显著差异( P < 0.05 )。  As can be seen from Table 2, the subjective symptoms and physical signs scores were significantly different before and after treatment (P < 0.05).
表 2 治疗前后症状体征比较结果  Table 2 Comparison of symptoms and signs before and after treatment
积分  Points
治疗前 治疗后 P值  Pre-treatment P value after treatment
症状体征总积分 13.12±2.81 3.78±1.70 <0.05  Total scores of symptoms and signs 13.12±2.81 3.78±1.70 <0.05
2.3 治疗前后各项指标的比较 2.3 Comparison of various indicators before and after treatment
由表 3 可以看出, 本中药组合物在延长泪膜破碎时间, 增加泪液流量、 改善角膜染色等方面, 治疗前后均有统计学差异。  It can be seen from Table 3 that the traditional Chinese medicine composition has statistical differences in prolonging tear film breakage time, increasing tear flow rate, and improving corneal staining.
表 3 治疗前后各项指标的比较(x±S)  Table 3 Comparison of indicators before and after treatment (x±S)
泪膜破裂时间 泪河高度 泪液分泌试-睑 角膜染色  Tear film rupture time tear river height tear secretion test - 角 corneal staining
(S) ( mm ) ( mm/5min ) (分) 治疗前 3.88±1.72 0.13±0.094 5.23±2.65 6.6±2.09 治疗后 4.42±1.61 0.14±0.095 7.10±3.05 3.62±1.90 (S) (mm) (mm/5min) (minutes) before treatment 3.88±1.72 0.13±0.094 5.23±2.65 6.6±2.09 After treatment 4.42±1.61 0.14±0.095 7.10±3.05 3.62±1.90
P值 <0.05 <0.05 <0.05 <0.05 P value <0.05 <0.05 <0.05 <0.05
2.4治疗前后主观症状比较结果如下: 2.4 The comparison of subjective symptoms before and after treatment is as follows:
表 4 治疗前后症状对比  Table 4 Symptom comparison before and after treatment
治疗前 治疗后  Before treatment
显效 有 st  Significantly
力口重  Heavy mouth
干涩感 68 (97.1%) 36 ( 52.9% ) 13 ( 19.1%) 18 (26.5%) Cognac 68 (97.1%) 36 ( 52.9% ) 13 ( 19.1% ) 18 (26.5%)
1 ( 1.5%) 1 ( 1.5%)
视疲劳 61(87.1%) 12 ( 19.8%) 11( 18.0%) 38 ( 62.2% ) 0 Visual fatigue 61 (87.1%) 12 ( 19.8%) 11 ( 18.0%) 38 ( 62.2% ) 0
(0) (0)
异物感 55 ( 78.6% ) 17(30.9%) 13(23.6%) 25(45.5%) 0 Foreign body sensation 55 (78.6%) 17 (30.9%) 13 (23.6%) 25 (45.5%) 0
(0) 视物模糊 43(61.4%) 12(27.9%) 12(27.9%) 19(44.2%) 0(0) Visual blur 43 (61.4%) 12 (27.9%) 12 (27.9%) 19 (44.2%) 0
(0) (0)
畏光 43(61.4%) 10(23.3%) 12(27.8%) 21(48.8%) 0 Photophobia 43 (61.4%) 10 (23.3%) 12 (27.8%) 21 (48.8%) 0
(0) (0)
眼红 35 ( 50.0% ) 9(25.7%) 7 ( 20.0% ) 19(54.3%) 0 Eye red 35 ( 50.0% ) 9 (25.7%) 7 ( 20.0% ) 19 (54.3%) 0
(0) (0)
疼痛 33(47.1%) 9(27.3%) 8(24.2%) 15(45.5%) 1 Pain 33 (47.1%) 9 (27.3%) 8 (24.2%) 15 (45.5%) 1
(3.0%) (3.0%)
流泪 24 ( 34.3% ) 6(25.0%) 7 ( 29.2% ) 11(45.8%) 0 Tears 24 ( 34.3% ) 6 (25.0%) 7 ( 29.2% ) 11 (45.8%) 0
(0) (0)
烧灼感 8 ( 22.9% ) 4 ( 50.0% ) 3 ( 37.5% ) 1 ( 12.5% ) 0 Burning sensation 8 ( 22.9% ) 4 ( 50.0% ) 3 ( 37.5% ) 1 ( 12.5% ) 0
(0) (0)
2.5治疗前后结膜充血症状改善情况如下: 2.5 The improvement of conjunctival hyperemia before and after treatment is as follows:
表 5治疗前后结膜充血程度改善情况 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后  Table 5: Improvement of conjunctival hyperemia before and after treatment Before treatment After treatment Before treatment After treatment Before treatment After treatment
充血程度 ( + + + ) 〉〉( + + ) ( + + ) »( + ) ( + ) » Degree of congestion ( + + + ) 〉〉 ( + + ) ( + + ) »( + ) ( + ) »
( - ) ( - )
例数 40 81 23 百分比 27.78 % 56.25 % 15.97%  Number of cases 40 81 23 Percent 27.78 % 56.25 % 15.97%
3、 结论 3. Conclusion
本中药组合物在延长泪膜破碎时间, 增加泪液流量、 改善角膜染色、 改善 结膜充血症状等方面, 都有显著改善效果。 对干眼症的治疗: 经统计痊愈率 8.33%, 显效率为 50.69%, 有效率为 38.89%, 无效率 2.09%, 总有效率为 97.91%; 表明本中药组合物对于治疗干眼症具有良好的作用。  The traditional Chinese medicine composition has significant improvement effects in prolonging tear film breakage time, increasing tear flow, improving corneal staining, and improving conjunctival hyperemia. Treatment of dry eye syndrome: The statistical cure rate is 8.33%, the effective rate is 50.69%, the effective rate is 38.89%, the inefficiency is 2.09%, and the total effective rate is 97.91%; indicating that the traditional Chinese medicine composition has good treatment for dry eye syndrome. The role.
下述实施例均能实现上述实验例的效果。  The effects of the above experimental examples can be achieved by the following examples.
具体实施方式 实施例 1: DETAILED DESCRIPTION OF THE INVENTION Example 1:
取黄芩 20g、 薄荷 15g、 天花粉 20g、 菊花 10g、 黄精 15g, 加 5重量倍量 水提取 3次, 每次 90分钟, 合并提取液, 过滤, 合并滤液, 备用, 取冰片 lg, 将冰片和滤液混合。 实施例 2: Take Astragalus 20g, Mint 15g, Trichosanthin 20g, Chrysanthemum 10g, Polygonatum 15g, add 5 times the amount of water for 3 times, each time for 90 minutes, combine the extracts, filter, combine the filtrate, reserve, take borneol lg, borneol and filtrate mixing. Example 2:
取黄芩 40g、 薄荷 10g、 天花粉 10g、 黄精 30g、 菊花 20g分别进行除杂、 洗净, 干燥, 加 6倍量(重量倍)水提取 3次, 每次 120分钟, 合并提取液, 过滤, 取滤液浓缩成相对密度为 1.15的清膏, 将冰片 3g和清膏混合, 加入片 剂常规辅料, 制片剂, 使用时将片剂用热水溶解蒸汽熏蒸给药。  Take Astragalus 40g, 10g of mint, 10g of trichosanthin, 30g of Polygonatum, 20g of chrysanthemum, respectively, remove, wash, dry, add 6 times (weight) water extraction 3 times, each time 120 minutes, combine the extract, filter, take The filtrate was concentrated to a clear density of 1.15. The borneol 3g and the clearing paste were mixed, and the tablet was added to a conventional excipient to prepare a tablet. When used, the tablet was fumigated with hot water to dissolve the steam.
实施例 3: Example 3:
取黄芩 38g、 薄荷 8g、 天花粉 15g、 黄精 35g、 菊花 18g分别进行除杂、 洗净, 干燥, 加 6倍量(重量倍)水提取 4次, 每次 60分钟, 合并提取液, 过滤, 取滤液浓缩成相对密度为 1.30的清膏, 将冰片 4g和清膏混合, 加入丸 剂常规辅料, 制成丸剂, 使用时将丸剂用热水溶解蒸汽熏蒸给药。  Take Astragalus 38g, Peppermint 8g, Trichosanthes 15g, Polygonatum 35g, Chrysanthemum 18g for impurity removal, washing, drying, add 6 times (weight) water extraction 4 times, each time 60 minutes, combine the extract, filter, take The filtrate was concentrated to a clear paste having a relative density of 1.30, 4 g of borneol and a clear paste were mixed, and a conventional excipient of the pellet was added to prepare a pellet, and the pellet was administered by steam fumigation with hot water.
实施例 4: Example 4:
取黄芩 25g、 薄荷 8g、 天花粉 15g、 黄精 30g、 菊花 18g分别进行除杂、 洗净, 干燥, 加 5倍量(重量倍)水提取 3次, 每次 120分钟, 合并提取液, 过滤, 取滤液浓缩成相对密度为 1.3的清膏, 将冰片 2g和清膏混合, 充分混 合后加入 45%乙醇沉淀 24小时, 沉淀后回收乙醇至无醇味, 冷藏 24小时后 装于无纺布载体中, 制成湿敷剂。  Take Astragalus 25g, Mint 8g, Trichosanthin 15g, Polygonatum 30g, Chrysanthemum 18g for impurity removal, washing, drying, add 5 times (weight) water extraction 3 times, each time 120 minutes, combine the extract, filter, take The filtrate was concentrated to a clear density of 1.3, the borneol 2g and the clear paste were mixed, thoroughly mixed and added to 45% ethanol for 24 hours. After the precipitation, the ethanol was recovered to an alcohol-free taste, and after 24 hours of refrigeration, it was placed in a non-woven carrier. , made into a wet compress.
实施例 5: Example 5
取黄芩 20g、 薄荷 7g、 天花粉 20g、 黄精 30g、 菊花 35g分别进行除杂、 洗净, 干燥, 加 7倍量(重量倍) 水提取 4次, 每次 90分钟, 合并提取液, 过滤, 取滤液浓缩成相对密度为 1.32的清膏, 将冰片 3g和清膏混合, 加入颗 粒剂常规辅料, 制成颗粒剂, 使用时将颗粒剂用热水溶解蒸汽熏蒸给药。  Take Astragalus 20g, Peppermint 7g, Trichosanthin 20g, Polygonatum 30g, Chrysanthemum 35g for impurity removal, washing, drying, add 7 times (weight) water extraction 4 times, each time 90 minutes, combine the extract, filter, take The filtrate was concentrated to a clear paste having a relative density of 1.32. The borneol 3g and the clear paste were mixed, and the granule conventional excipient was added to prepare a granule. When used, the granules were fumigated with hot water dissolved steam.

Claims

权利要求书 Claim
1、 一种外用治疗干眼症的中药组合物, 其特征在于所述中药组合物的原 料药组成为:  A traditional Chinese medicine composition for external use for treating dry eye, characterized in that the raw material composition of the traditional Chinese medicine composition is:
黄芩 5-50重量份 薄荷 3-45重量份 天花粉 5-50重量份 菊花 1-40重量份 黄精 3-45重量份 冰片 0.1-5重量份。 Astragalus 5-50 parts by weight Mint 3-45 parts by weight Trichosanthin 5-50 parts by weight Chrysanthemum 1-40 parts by weight Yellow essence 3-45 parts by weight Boring piece 0.1-5 parts by weight.
2、 如权利要求 1所述的中药组合物, 其特征在于所述中药组合物的原料 药组成为: 2. The traditional Chinese medicine composition according to claim 1, wherein the raw material composition of the traditional Chinese medicine composition is:
黄芩 10-40重量份 薄荷 5-35重量份 天花粉 10-40重量份 菊花 5-30重量份 黄精 5-35重量份 冰片 0.5-3重量份。 Astragalus 10-40 parts by weight Mint 5-35 parts by weight Trichosanthin 10-40 parts by weight Chrysanthemum 5-30 parts by weight Yellow essence 5-35 parts by weight Boring piece 0.5-3 parts by weight.
3、 如权利要求 1所述的中药组合物, 其特征在于所述中药组合物的原料 药组成为: 3. The traditional Chinese medicine composition according to claim 1, wherein the raw material composition of the traditional Chinese medicine composition is:
黄芩 15-30重量份 薄荷 10-25重量份 天花粉 15-30重量份 菊花 7-20重量份 黄精 10-25重量份 冰片 0.7-1.5重量份。 Astragalus 15-30 parts by weight Mint 10-25 parts by weight Trichosanthin 15-30 parts by weight Chrysanthemum 7-20 parts by weight Yellow essence 10-25 parts by weight Boring piece 0.7-1.5 parts by weight.
4、 如权利要求 1所述的中药组合物, 其特征在于所述中药组合物的原料 药组成为: 4. The traditional Chinese medicine composition according to claim 1, wherein the raw material composition of the traditional Chinese medicine composition is:
黄芩 20重量份 薄荷 15重量份 天花粉 20重量份  Astragalus 20 parts by weight Mint 15 parts by weight Trichosanthin 20 parts by weight
菊花 10重量份 黄精 15重量份 冰片 1重量份。  Chrysanthemum 10 parts by weight Huang Jing 15 parts by weight Boron 1 part by weight.
5、 如权利要求 1-4任一所述的中药组合物的制备方法, 其特征在于该方 法为: 取黄芩、 薄荷、 天花粉、 黄精、 菊花, 加 2 ~ 8 重量倍量水提取 1 ~ 4 次, 每次 30 ~ 150分钟, 合并提取液, 过滤, 取滤液浓缩成相对密度为 1.05 ~ 1.35的清膏, 将冰片和清膏混合, 加入常规辅料制成临床接受的剂型。  The method for preparing a traditional Chinese medicine composition according to any one of claims 1 to 4, wherein the method comprises: taking astragalus, mint, trichosanthin, huangjing, chrysanthemum, and adding 2 to 8 times by weight of water to extract 1 to 4 Then, each time 30 ~ 150 minutes, the extracts were combined, filtered, and the filtrate was concentrated to a clear density of 1.05 ~ 1.35. The borneol and the clear paste were mixed, and the conventional excipients were added to make a clinically accepted dosage form.
6、 如权利要求 1-4任一所述的中药组合物在制备通过外部给药治疗干眼 症药物中的应用。  6. Use of a traditional Chinese medicine composition according to any one of claims 1 to 4 for the preparation of a medicament for the treatment of dry eye by external administration.
7、 如权利要求 6所述的中药组合物在制备通过雾化给药治疗干眼症药物 中的应用。  7. The use of a traditional Chinese medicine composition according to claim 6 for the preparation of a medicament for treating dry eye by atomization.
PCT/CN2012/081389 2011-09-27 2012-09-14 Traditional chinese medicine composition for external use in treating xerophthalmia and the preparation method thereof WO2013044736A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011103057972A CN102357196B (en) 2011-09-27 2011-09-27 External traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof
CN201110305797.2 2011-09-27

Publications (1)

Publication Number Publication Date
WO2013044736A1 true WO2013044736A1 (en) 2013-04-04

Family

ID=45582613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/081389 WO2013044736A1 (en) 2011-09-27 2012-09-14 Traditional chinese medicine composition for external use in treating xerophthalmia and the preparation method thereof

Country Status (2)

Country Link
CN (1) CN102357196B (en)
WO (1) WO2013044736A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102698079B (en) * 2012-06-19 2013-10-16 成都中医药大学附属医院 Medicine composition for treating xerophthalmia and preparation method and application thereof
CN102973842B (en) * 2012-12-04 2014-04-02 武传红 Traditional Chinese medicine fuming and washing liquid for treating xerophthalmia
CN102920911B (en) * 2012-12-05 2014-05-07 青岛市中心医院 Traditional Chinese medicine for treating keratoconjunctivitis sicca and preparation method thereof
CN104274601B (en) * 2013-07-03 2017-12-12 郑州市新视明科技工程有限公司 A kind of Chinese medicine composition of external curing xerophthalmia and preparation method thereof
CN104274600B (en) * 2013-07-03 2017-12-29 郑州市新视明科技工程有限公司 A kind of new application of Chinese medicine composition
CN104367832A (en) * 2014-11-06 2015-02-25 青岛市市立医院 Compound dendrobe eye drops for treating xerophthalmia and preparation method thereof
CN115105520B (en) * 2022-07-15 2023-10-20 中国科学技术大学 Application of baicalin in preparation of medicine for treating amblyopia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1285349C (en) * 2004-10-13 2006-11-22 凌沛学 Chinese medicinal formulation for treating asthenopia syndrome and its preparation method
CN101843781B (en) * 2010-05-28 2011-05-25 郑州市新视明科技工程有限公司 Chinese medicinal composition for preventing and treating xerophthalmia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GONG, J. Y. ET AL.: "Research advance on xerophthalmia treated by specialized herbal formulae", SHANGHAI JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 44, no. 11, 30 November 2010 (2010-11-30), pages 83 - 84 *
WEI, B. C. ET AL.: "Current situation of Chinese medicine treatment of xerophthalmia", HEBEI JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 32, no. 9, 30 September 2010 (2010-09-30), pages 1430 *

Also Published As

Publication number Publication date
CN102357196A (en) 2012-02-22
CN102357196B (en) 2013-04-03

Similar Documents

Publication Publication Date Title
WO2013044736A1 (en) Traditional chinese medicine composition for external use in treating xerophthalmia and the preparation method thereof
CN102698079B (en) Medicine composition for treating xerophthalmia and preparation method and application thereof
CN103110810A (en) Traditional Chinese medicine preparation for treating dry eye diseases
CN111544390B (en) Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method
JP2021505650A (en) Ophthalmic drug preparations and their use
CN102362924A (en) Medicinal composition for treating ophthalmic diseases and preparation method thereof
CN102755361A (en) Moist towelette for preventing and curing rhinitis and preparation method for moist towelette
KR20170004245A (en) Pharmaceutical composition for preventing or treating ocular diseases
CN105106318B (en) A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia
CN100388923C (en) Chinese-medicinal preparation and making method for treating acute corneitis and releasing visual fatigue
CN111297948B (en) Eye patch for treating demodex blepharitis and preparation method
CN110123877B (en) Hot compress bag for treating xerophthalmia and preparation method thereof
CN105902686A (en) In-situ gel eyewash containing nano-carbon crystals and preparation method thereof
CN113786452A (en) Traditional Chinese medicine composition for treating allergic conjunctivitis and/or allergic rhinitis
CN109288970B (en) Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof
CN104606397A (en) Medicine for oral administration for treating haemorrhage after eye injury and preparation method thereof
CN104940372A (en) Externally applied drug for treating acute conjunctivitis and preparation method thereof
JP5045968B1 (en) Dry eye treatment herbal medicine composition
CN110051778B (en) Sore throat relieving tea for treating chronic pharyngitis and preparation method thereof
CN110101799B (en) Tea bag for treating xerophthalmia and preparation method thereof
CN102078287B (en) Ophthalmic gel of artificial musk and preparation method thereof
CN106822671A (en) medicine for treating conjunctivitis
CN104958400A (en) Oculentum for treating acute conjunctivitis and preparation method thereof
CN113876882A (en) Traditional Chinese medicine eye fumigating composition for treating dry eye, traditional Chinese medicine eye fumigating bag, fumigant, atomized preparation or eye spray and preparation method
CN105055764A (en) Medicine for treating chronic angle-closure glaucoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12837404

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12837404

Country of ref document: EP

Kind code of ref document: A1